Feature Channels

Blood Disorders

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Keywords:

Top Blood Transfusion-Related Complication More Common Than Previously Reported

Two studies published in the January issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists® (ASA®), shed new light on the prevalence of transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO), the number one and two leading causes of blood transfusion-related deaths in the United States.

View

Medicine

Channels:

Keywords:

Experts in Leukemia and Bone Marrow Transplant Prepare for Upcoming Pivotal Trial of Innovative Targeted Payload Immunotherapy

DraganPhoto.JPG

If approved, Iomab-B should increase the number of patients eligible for curative bone marrow transplant (BMT, also known as HSCT) and improve clinical outcomes.

View | Comment

Medicine

Channels:

Keywords:

Experts in Leukemia Treatment Support Ongoing Trials for Novel Alpha-Radiolabeled Antibody Treatment

ps700_6713_Joseph-Jurcic.jpg

Since intensive chemotherapy is associated with a high mortality rate and limited benefits to high risk patients, low intensity treatments such as Actimab-A could potentially extend overall survival in elderly patients while significantly decreasing traditional chemotherapy related toxicities, including treatment related early mortality.

View | Comment

Medicine

Channels:

Keywords:

PRM-151 Therapy Well Tolerated in Patients with Advanced Myelofibrosis

124090_Verstovsek_S3.jpg

A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.

View | Comment

Medicine

Channels:

Keywords:

Experimental Gene Therapy Successful in Certain Lymphomas and Leukemia

101115_Kebriaei_P1.jpg

Study results of CD19-directed chimeric antigen receptor (CAR) therapy using the Sleeping Beauty non-viral transduction system to modify T cells has demonstrated further promise in patients with advanced hematologic malignancies.

View | Comment

Medicine

Channels:

Keywords:

Penn Medicine Researchers Announce Latest Results of Investigational Cellular Therapy CTL019

The latest results of clinical trials of more than 125 patients testing an investigational personalized cellular therapy known as CTL019 will be presented by a University of Pennsylvania research team at the 56th American Society of Hematology Annual Meeting and Exposition. Highlights of the new trial results will include a response rate of more than 90 percent among pediatric acute lymphoblastic leukemia patients, and results from the first lymphoma trials testing the approach, including a 100 percent response rate among follicular lymphoma patients and 45 percent response rate among those with diffuse large B-cell lymphoma.

View | Comment

Medicine

Channels:

Keywords:

Combination Therapy Shown as Effective for Higher-Risk DS/AML Patients

197099_DiNardo_C.jpg

A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.

View | Comment

Medicine

Channels:

Keywords:

Study Shows Improved Survival in Aggressive Acute Myeloid Leukemia

122113_Ravandi-Kashani_F.jpg

Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.

View | Comment

Medicine

Channels:

Keywords:

Memorial Sloan Kettering Study Shows New Kind of Targeted Drug Has Promise for Leukemia Patients

A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial.

View | Comment

Medicine

Channels:

Keywords:

Studies Led by Memorial Sloan Kettering Investigators Show Immunotherapy Drugs Improve Outcomes in Hodgkin Lymphoma Patients

In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. For Classical Hodgkin lymphoma patients, two phase I studies are already demonstrating dramatic results.

View | Comment